BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16795005)

  • 1. 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity.
    Ohrui H
    Chem Rec; 2006; 6(3):133-43. PubMed ID: 16795005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2'-Deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma.
    Ohrui H; Kohgo S; Hayakawa H; Kodama E; Matsuoka M; Nakata T; Mitsuya H
    Nucleic Acids Symp Ser (Oxf); 2006; (50):1-2. PubMed ID: 17150787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma.
    Ohrui H; Kohgo S; Hayakawa H; Kodama E; Matsuoka M; Nakata T; Mitsuya H
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1543-6. PubMed ID: 18066823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.
    Cancio R; Mai A; Rotili D; Artico M; Sbardella G; Clotet-Codina I; Esté JA; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
    ChemMedChem; 2007 Apr; 2(4):445-8. PubMed ID: 17323401
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.
    Ohrui H
    Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(3):53-65. PubMed ID: 21422739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Cesarini S; Spallarossa A; Ranise A; Schenone S; Bruno O; La Colla P; Casula L; Collu G; Sanna G; Loddo R
    Bioorg Med Chem; 2008 Jun; 16(12):6353-63. PubMed ID: 18502646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
    J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 2).
    Lavecchia A; Costi R; Artico M; Miele G; Novellino E; Bergamini A; Crespan E; Maga G; Di Santo R
    ChemMedChem; 2006 Dec; 1(12):1379-90. PubMed ID: 17089434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
    Monforte AM; Rao A; Logoteta P; Ferro S; De Luca L; Barreca ML; Iraci N; Maga G; De Clercq E; Pannecouque C; Chimirri A
    Bioorg Med Chem; 2008 Aug; 16(15):7429-35. PubMed ID: 18585918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
    Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
    J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.
    Takamatsu Y; Das D; Kohgo S; Hayashi H; Delino NS; Sarafianos SG; Mitsuya H; Maeda K
    Cell Chem Biol; 2018 Oct; 25(10):1268-1278.e3. PubMed ID: 30174310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4'C-ethynyl-thymidine acts as a chain terminator during DNA-synthesis catalyzed by HIV-1 reverse transcriptase.
    Summerer D; Marx A
    Bioorg Med Chem Lett; 2005 Feb; 15(4):869-71. PubMed ID: 15686877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
    Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
    J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
    Persaud D; Palumbo P; Ziemniak C; Chen J; Ray SC; Hughes M; Havens P; Purswani M; Gaur AH; Chadwick EG;
    J Infect Dis; 2007 May; 195(10):1402-10. PubMed ID: 17436219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Dunn JP; Li Y; Heilek G; Dunten P; Elworthy TR; Han X; Harris SF; Hirschfeld DR; Hogg JH; Huber W; Kaiser AC; Kertesz DJ; Kim W; Mirzadegan T; Roepel MG; Saito YD; Silva TM; Swallow S; Tracy JL; Villasenor A; Vora H; Zhou AS; Klumpp K
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4352-4. PubMed ID: 18632268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
    Nakata H; Amano M; Koh Y; Kodama E; Yang G; Bailey CM; Kohgo S; Hayakawa H; Matsuoka M; Anderson KS; Cheng YC; Mitsuya H
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2701-8. PubMed ID: 17548498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants.
    Su DS; Lim JJ; Tinney E; Wan BL; Young MB; Anderson KD; Rudd D; Munshi V; Bahnck C; Felock PJ; Lu M; Lai MT; Touch S; Moyer G; Distefano DJ; Flynn JA; Liang Y; Sanchez R; Prasad S; Yan Y; Perlow-Poehnelt R; Torrent M; Miller M; Vacca JP; Williams TM; Anthony NJ
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5119-23. PubMed ID: 19631528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.